These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 3102804)

  • 1. Attenuated development of hypertension by chronic administration of bromocriptine in Doca-salt hypertensive rats.
    Kambara S; Yoshimura M; Okabayashi H; Takahashi H; Ijichi H
    Jpn Circ J; 1986 Nov; 50(11):1120-7. PubMed ID: 3102804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathophysiological role of dopamine on the development of hypertension in rats.
    Yoshimura M; Kambara S; Okabayashi H; Ikegaiki I; Matsuzawa M; Suga K; Takahashi H; Ijichi H
    Jpn Circ J; 1987 Oct; 51(10):1226-31. PubMed ID: 3430692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Central bromocriptine-induced tachycardia is reversed to bradycardia in conscious, deoxycorticosterone acetate-salt hypertensive rats.
    Lahlou S
    Pharmacol Toxicol; 2001 May; 88(5):238-43. PubMed ID: 11393583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypotensive action of bromocriptine in the DOCA-salt hypertensive rat: contribution of spinal dopamine receptors.
    Lahlou S; Duarte GP
    Fundam Clin Pharmacol; 1998; 12(6):599-606. PubMed ID: 9917201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced depressor effect of bromocriptine in the DOCA/NaCl hypertensive rat.
    Nagahama S; Chen YF; Oparil S
    Am J Physiol; 1985 Jul; 249(1 Pt 2):H64-70. PubMed ID: 2861750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular responses to intrathecal dopamine receptor agonists in conscious DOCA-salt hypertensive rats.
    Lahlou S
    Fundam Clin Pharmacol; 1999; 13(6):624-34. PubMed ID: 10626749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of the renal nerves in the maintenance of DOCA-salt hypertension in the rat. Influence on the renal vasculature and sodium excretion.
    Katholi RE; Naftilan AJ; Bishop SP; Oparil S
    Hypertension; 1983; 5(4):427-35. PubMed ID: 6345357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blunted pressor responsiveness to quinpirole, a specific dopamine D2 receptor agonist, in conscious deoxycorticosterone acetate/NaCl hypertensive rats is related to atrial natriuretic peptide release.
    Chen YF; Jin HK; Paul R; Nagahama S
    J Pharmacol Exp Ther; 1988 Aug; 246(2):485-92. PubMed ID: 2969976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retardation of the development of hypertension in DOCA salt rats by taurine supplement.
    Inoue A; Takahashi H; Lee LC; Sasaki S; Kohno Y; Takeda K; Yoshimura M; Nakagawa M
    Cardiovasc Res; 1988 May; 22(5):351-8. PubMed ID: 3191519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of norepinephrine release from vascular adrenergic neurons by oral administration of beta-blocker in DOCA-salt hypertension.
    Tsuda K; Masuyama Y
    Am J Hypertens; 1991 Jan; 4(1 Pt 1):68-71. PubMed ID: 2007000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of alpha-lipoic acid on deoxycorticosterone acetate-salt-induced hypertension in rats.
    Takaoka M; Kobayashi Y; Yuba M; Ohkita M; Matsumura Y
    Eur J Pharmacol; 2001 Jul; 424(2):121-9. PubMed ID: 11476758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in renal and central noradrenergic activity with potassium in DOCA-salt rats.
    Fujita T; Sato Y
    Am J Physiol; 1984 May; 246(5 Pt 2):F670-5. PubMed ID: 6144278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bromocriptine-induced decrease in blood pressure in conscious spontaneously hypertensive rats: evidence for a peripheral site of action.
    van den Buuse M; Lambrechts AC
    J Pharm Pharmacol; 1989 Sep; 41(9):644-6. PubMed ID: 2573712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood pressure and renal responses to synthetic rat atrial natriuretic factor in deoxycorticosterone acetate-salt hypertension.
    Kohzuki M; Abe K; Yasujima M; Kasai Y; Hiwatari M; Kanazawa M; Sato M; Omata K; Kudo K; Takeuchi K
    Tohoku J Exp Med; 1989 Apr; 157(4):301-11. PubMed ID: 2525826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of presynaptic beta 2-adrenergic facilitation in the development and maintenance of DOCA-salt hypertension.
    Moreau P; Drolet G; Yamaguchi N; de Champlain J
    Am J Hypertens; 1993 Dec; 6(12):1016-24. PubMed ID: 7907884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of K+-canrenoate on the development of DOCA-salt hypertension.
    Vargas F; Haro JM; Jodar E; Soler A; Garcia del Rio C
    J Pharm Pharmacol; 1989 May; 41(5):335-8. PubMed ID: 2569521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paraventricular nucleus lesions attenuate the development of hypertension in DOCA/salt-treated rats.
    Nakata T; Takeda K; Itho H; Hirata M; Kawasaki S; Hayashi J; Oguro M; Sasaki S; Nakagawa M
    Am J Hypertens; 1989 Aug; 2(8):625-30. PubMed ID: 2570597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic treatment with mianserin prevents DOCA-salt hypertension in rats--evidence for the involvement of central 5-HT2 receptors.
    Silva AL; Cabral AM; Abreu GR; Pires JG; Bissoli NS; Ramage AG
    Eur J Pharmacol; 2005 Aug; 518(2-3):152-7. PubMed ID: 16014306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitory effect of potassium on blood pressure in DOCA salt hypertension in rats.
    Suzuki H; Kondo K; Saruta T
    Acta Endocrinol (Copenh); 1981 Aug; 97(4):525-32. PubMed ID: 7270008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of the depressor effect of bromocriptine in the spontaneously hypertensive rat.
    Nagahama S; Chen YF; Oparil S
    J Pharmacol Exp Ther; 1984 Feb; 228(2):370-5. PubMed ID: 6363675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.